Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-23
    E.g., 2018-06-23

Articles

257317 items
12:00 AM, Apr 10, 1995  |  BC Week In Review | Clinical News  |  Clinical Status

Gene therapy with adenovirus vector containing the normal CF gene: Began trial to determine safety of delivery by bronchoscope into one lobe of each patient's l

Genzyme Corp. (GENZ), Cambridge, Mass.   Product: Gene therapy with adenovirus vector containing the normal CF gene   Indication: Cystic fibrosis   Status: Began trial to determine safety of delivery by bronchoscope into one lobe of each patient's...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Clinical News  |  Clinical Status

R-albuterol: Began Phase II trial to compare bronchodilatory effect with racemic albuterol in 20 patients to be enrolled in the placebo-controlled, double-blind

Sepracor Inc. (SEPR), Marlborough, Mass.   Product: R-albuterol, the separated isomer of racemic, R,S-albuterol, a currently marketed bronchodilator   Indication: Asthma   Status: Began Phase II trial to compare bronchodilatory effect with racemic albuterol in 20 patients to...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Deals

Genetics Institute deal

Genetics Institute Inc. (GENIZ)   GENIZ (Cambridge, Mass.) and Sofamor Danek Group Inc. (Memphis, Tenn.) said their agreement to commercialize bone morphogenic protein for spinal reconstruction has become effective. The previously announced agreement (see BioCentury,...
12:00 AM, Apr 10, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Univax Biologics Inc. (UNVX) Dillon, Read's King initiated coverage with a "buy" and a one-year price target of $19-20, based on his characterization of the company's proven technology with low product risk, experienced, product-focused management,...
12:00 AM, Apr 10, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Vical Inc. (VICL) Fariba Ghodsian of Wedbush Morgan Securities began coverage with a "buy" and a 12-month price target of $9-10. She said the San Diego company has attractive technology based on two platform technologies...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Deals

Neose Pharmaceuticals Inc. deal

Abbott will make undisclosed regular payments to the privately held company over the next 30 months, as well as a milestone payment upon commercialization of the product that incorporates the carbohydrates. Under a 1992...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Deals

Oxford Molecular deal

Oxford (Mountain View, Calif.) received exclusive worldwide co-distribution rights to the University of California at San Francisco's AMBER family of molecular-mechanics simulation programs. AMBER consists of a set of simulation tools for the study of...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Other News

Aastrom other research news

The privately held company received a $520,000 Phase II SBIR award from the National Institute of Diabetes, Digestive and Kidney Diseases to further develop its Cell Production System, which produces expanded numbers of stem and...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Clinical News  |  Clinical Status

Heparin Removal Device: Began a multi-center device trial in 30 patients in Europe

Research Industries Corp. (REIC), Salt Lake City   Product: Heparin Removal Device, which uses plasmapheresis outside the body, passing blood plasma through a hollow fiber tube containing a positively charged material that binds the negatively charged...
12:00 AM, Apr 10, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Vertex Pharmaceuticals Inc. (VRTX) David Stone of Cowen & Co. said the publication in Nature of a Merck paper on HIV resistance to protease inhibitors is old news and shouldn't be viewed negatively (see page...

Pages